Danielle M. Santarelli
Research Subjects
Danielle M. Santarelli has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Marc Russo
Hunter Pain Specialists, Broadmeadow, NSW, Australia; Genesis Research Services, Broadmeadow, NSW, Australia; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia
18 shared publications - Paul A. Tooney
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia
5 shared publications - Murray J. Cairns
The University of Newcastle
4 shared publications - Paul J. Austin
Brain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
4 shared publications - Barbara Fazekas de St Groth
Charles Perkins Centre, The University of Sydney, Sydney, Australia
3 shared publications Natalie J. Beveridge
To whom correspondence should be addressed; School of Biomedical Sciences & Pharmacy, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia; tel: +61-2-4921-8670, fax: +61-2-4921-7903,
3 shared publications
Latest Publications
- 3 February 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (6) , 337-347
Systematic review and meta-analysis of conventional medical management in a patient population with refractory chronic pain suitable to receive a spinal cord stimulation system
Aim: The aim of this review was to systematically identify all evidence that used conventional medical management (CMM) as a comparator in randomized controlled trials (RCTs) of spinal cord stimulation (SCS) therapy, and to conduct a meta-analysis to investigate if continued CMM provides statistical or clinically meaningful pain relief and whether CMM effects have improved over the last few decades. Methods: Databases were searched from inception to June 2024 for RCTs that compared SCS to CMM. The primary outcome of the review was absolute change in pain intensity from baseline to the last available follow-up in the CMM group, measured using a visual analogue scale or numerical rating scale. The measure of treatment effect for absolute change and percentage change in pain intensity from baseline was mean difference (MD) and 95% confidence interval (CI). Risk of bias (RoB) was assessed by using the revised Cochrane RoB tool. The protocol for this review is registered on PROSPERO (CRD42023449215). Results: Meta-analysis of absolute change in pain intensity from baseline to last follow-up shows that CMM is not associated with any significant reductions in pain intensity (MD −0.11; 95% CI: −0.32 to 0.11; moderate certainty). Similar results were observed for percent change in pain intensity from baseline to last follow-up (MD −3.22%; 95% CI: −12.59% to 6.14%; moderate certainty). No significant differences were observed when considering decade of publication of the RCT for absolute (P = .065; moderate certainty) or percent change in pain intensity (P = 0.524; moderate certainty). Meta-analysis for 6-month follow-up and sensitivity analysis shows similar numerical results. Conclusion: Our findings show that continued CMM for a population eligible for SCS does not provide meaningful pain relief and has not considerably changed over the last few decades. The use of CMM as the control to evaluate relative SCS treatment effects should be reassessed.
- 3 February 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (6) , 337-347
Systematic review and meta-analysis of conventional medical management in a patient population with refractory chronic pain suitable to receive a spinal cord stimulation system
Aim: The aim of this review was to systematically identify all evidence that used conventional medical management (CMM) as a comparator in randomized controlled trials (RCTs) of spinal cord stimulation (SCS) therapy, and to conduct a meta-analysis to investigate if continued CMM provides statistical or clinically meaningful pain relief and whether CMM effects have improved over the last few decades. Methods: Databases were searched from inception to June 2024 for RCTs that compared SCS to CMM. The primary outcome of the review was absolute change in pain intensity from baseline to the last available follow-up in the CMM group, measured using a visual analogue scale or numerical rating scale. The measure of treatment effect for absolute change and percentage change in pain intensity from baseline was mean difference (MD) and 95% confidence interval (CI). Risk of bias (RoB) was assessed by using the revised Cochrane RoB tool. The protocol for this review is registered on PROSPERO (CRD42023449215). Results: Meta-analysis of absolute change in pain intensity from baseline to last follow-up shows that CMM is not associated with any significant reductions in pain intensity (MD −0.11; 95% CI: −0.32 to 0.11; moderate certainty). Similar results were observed for percent change in pain intensity from baseline to last follow-up (MD −3.22%; 95% CI: −12.59% to 6.14%; moderate certainty). No significant differences were observed when considering decade of publication of the RCT for absolute (P = .065; moderate certainty) or percent change in pain intensity (P = 0.524; moderate certainty). Meta-analysis for 6-month follow-up and sensitivity analysis shows similar numerical results. Conclusion: Our findings show that continued CMM for a population eligible for SCS does not provide meaningful pain relief and has not considerably changed over the last few decades. The use of CMM as the control to evaluate relative SCS treatment effects should be reassessed.
- 8 October 2023
- Published by Index Copernicus in Ból
- Vol. 24 (3) , 21-34
REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?
- 8 October 2023
- Published by Index Copernicus in Ból
- Vol. 24 (3) , 21-34
REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?
- Open Access
- 5 September 2023
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (1) , 5-7
Progressing into a new paradigm: how we must leave the past behind if we want a change in pain research outcomes
Marc A Russo, MBBS, Danielle M Santarelli, PhD, Paul J Austin, PhD, Brett A Graham, PhD; Progressing into a new paradigm: how we must leave the past behind if w
- 5 September 2023
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (1) , 5-7
Open AccessProgressing into a new paradigm: how we must leave the past behind if we want a change in pain research outcomes
Marc A Russo, MBBS, Danielle M Santarelli, PhD, Paul J Austin, PhD, Brett A Graham, PhD; Progressing into a new paradigm: how we must leave the past behind if w
- 28 September 2022
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 19 (2) , e53-e54
Spinal Cord Stimulator Complications Reported to the Australian Therapeutic Goods Administration
- 28 September 2022
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 19 (2) , e53-e54
Spinal Cord Stimulator Complications Reported to the Australian Therapeutic Goods Administration
- 17 May 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (1) , 3-13
Ambroxol for neuropathic pain: hiding in plain sight?
Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Nav) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.
- 17 May 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (1) , 3-13
Ambroxol for neuropathic pain: hiding in plain sight?
Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Nav) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.
- Open Access
- 1 December 2021
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 3897-3907
A History of the Development of Radiofrequency Neurotomy
The technique of lumbar medial branch radiofrequency neurotomy for facet joint pain has an intriguing history involving a diverse timeline of medical specialists. This paper aims to chart the pathway that led to its invention and the series of modifications and refinements that have led to modern practice. The story begins with the treatment of World War I soldiers by Nesfield, who used scalpels to cut “trapped” nerves. Inspired by Nesfield’s treatment, Rees developed the “percutaneous rhizolysis” technique in 1960. Shealy was the first to use radiofrequency electrodes for denervation of the facet joints, introducing his technique in 1971. Several radiofrequency electrode developments came about from collaborations with Cosman medical device entrepreneurs during the 1970s, including the Shealy Rhizolysis Kit, the Ray Rhizotomy Electrode, and the Sluijter-Mehta Kit. Subsequent dissections of Rees’ technique and modification of Shealy’s procedure by Bogduk saw the development of “percutaneous lumbar medial branch neurotomy” in 1980 by Bogduk and Long. Bogduk continued to contribute significantly to validation, refinement and acceptance of the technique. In 1998, the technique of pulsed radiofrequency was invented by Sluijter, Cosman, Rittman and van Kleef. Subsequent innovations have consisted of cooled radiofrequency neurotomy, multi-tined cannulae, endoscopic systems, and alternative denervation targets, such as the facet joint capsule. As we pass the first 100 years of the story, we believe there are more chapters to be written on this fascinating subject.
- 1 December 2021
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 3897-3907
Open AccessA History of the Development of Radiofrequency Neurotomy
The technique of lumbar medial branch radiofrequency neurotomy for facet joint pain has an intriguing history involving a diverse timeline of medical specialists. This paper aims to chart the pathway that led to its invention and the series of modifications and refinements that have led to modern practice. The story begins with the treatment of World War I soldiers by Nesfield, who used scalpels to cut “trapped” nerves. Inspired by Nesfield’s treatment, Rees developed the “percutaneous rhizolysis” technique in 1960. Shealy was the first to use radiofrequency electrodes for denervation of the facet joints, introducing his technique in 1971. Several radiofrequency electrode developments came about from collaborations with Cosman medical device entrepreneurs during the 1970s, including the Shealy Rhizolysis Kit, the Ray Rhizotomy Electrode, and the Sluijter-Mehta Kit. Subsequent dissections of Rees’ technique and modification of Shealy’s procedure by Bogduk saw the development of “percutaneous lumbar medial branch neurotomy” in 1980 by Bogduk and Long. Bogduk continued to contribute significantly to validation, refinement and acceptance of the technique. In 1998, the technique of pulsed radiofrequency was invented by Sluijter, Cosman, Rittman and van Kleef. Subsequent innovations have consisted of cooled radiofrequency neurotomy, multi-tined cannulae, endoscopic systems, and alternative denervation targets, such as the facet joint capsule. As we pass the first 100 years of the story, we believe there are more chapters to be written on this fascinating subject.
- Open Access
- 9 June 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 15, 100283
T lymphocyte and monocyte subsets are dysregulated in type 1 diabetes patients with peripheral neuropathic pain
- 9 June 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 15, 100283
Open AccessT lymphocyte and monocyte subsets are dysregulated in type 1 diabetes patients with peripheral neuropathic pain
- Open Access
- 1 December 2019
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 17 (6) , 623-634
Schizophrenia-Associated MicroRNA–Gene Interactions in the Dorsolateral Prefrontal Cortex
Schizophrenia-associated anomalies in gene expression in postmortem brain can be attributed to a combination of genetic and environmental influences. Given the small effect size of common variants, it is likely that we may only see the combined impact of some of these at the pathway level in small postmortem studies. At the gene level, however, there may be more impact from common environmental exposures mediated by influential epigenomic modifiers, such as microRNA (miRNA). We hypothesise that dysregulation of miRNAs and their alteration of gene expression have significant implications in the pathophysiology of schizophrenia. In this study, we integrate changes in cortical gene and miRNA expression to identify regulatory interactions and networks associated with the disorder. Gene expression analysis in post-mortem prefrontal dorsolateral cortex (BA 46) (n = 74 matched pairs of schizophrenia, schizoaffective, and control samples) was integrated with miRNA expression in the same cohort to identify gene–miRNA regulatory networks. A significant gene–miRNA interaction network was identified, including miR-92a, miR-495, and miR-134, which converged with differentially expressed genes in pathways involved in neurodevelopment and oligodendrocyte function. The capacity for miRNA to directly regulate gene expression through respective binding sites in BCL11A, PLP1, and SYT11 was also confirmed to support the biological relevance of this integrated network model. The observations in this study support the hypothesis that miRNA dysregulation is an important factor in the complex pathophysiology of schizophrenia.
- 1 December 2019
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 17 (6) , 623-634
Open AccessSchizophrenia-Associated MicroRNA–Gene Interactions in the Dorsolateral Prefrontal Cortex
Schizophrenia-associated anomalies in gene expression in postmortem brain can be attributed to a combination of genetic and environmental influences. Given the small effect size of common variants, it is likely that we may only see the combined impact of some of these at the pathway level in small postmortem studies. At the gene level, however, there may be more impact from common environmental exposures mediated by influential epigenomic modifiers, such as microRNA (miRNA). We hypothesise that dysregulation of miRNAs and their alteration of gene expression have significant implications in the pathophysiology of schizophrenia. In this study, we integrate changes in cortical gene and miRNA expression to identify regulatory interactions and networks associated with the disorder. Gene expression analysis in post-mortem prefrontal dorsolateral cortex (BA 46) (n = 74 matched pairs of schizophrenia, schizoaffective, and control samples) was integrated with miRNA expression in the same cohort to identify gene–miRNA regulatory networks. A significant gene–miRNA interaction network was identified, including miR-92a, miR-495, and miR-134, which converged with differentially expressed genes in pathways involved in neurodevelopment and oligodendrocyte function. The capacity for miRNA to directly regulate gene expression through respective binding sites in BCL11A, PLP1, and SYT11 was also confirmed to support the biological relevance of this integrated network model. The observations in this study support the hypothesis that miRNA dysregulation is an important factor in the complex pathophysiology of schizophrenia.
- 20 November 2019
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 23 (5) , 687-697
A Novel Composite Metric for Predicting Patient Satisfaction With Spinal Cord Stimulation
- 20 November 2019
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 23 (5) , 687-697
A Novel Composite Metric for Predicting Patient Satisfaction With Spinal Cord Stimulation
- Open Access
- 3 April 2019
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 16 (1) , 70
Correction to: Expansion and activation of distinct central memory T lymphocyte subsets in complex regional pain syndrome
Following publication of the original article [1], the authors reported an error in Figure 4 as the wrong figure was used.
- 3 April 2019
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 16 (1) , 70
Open AccessCorrection to: Expansion and activation of distinct central memory T lymphocyte subsets in complex regional pain syndrome
Following publication of the original article [1], the authors reported an error in Figure 4 as the wrong figure was used.